Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: Prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis

被引:11
作者
Sperling, RT [1 ]
Pinto, DS [1 ]
Ho, KKL [1 ]
Carrozza, JP [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Sect Intervent Cardiol, Boston, MA 02215 USA
关键词
glycoproteins; revascularization; pharmacokinetics; kidney;
D O I
10.1002/ccd.10576
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report the time course to the restoration of normal platelet aggregation in three patients who were treated with eptifibatide in the setting of severe renal failure. There was prolonged platelet inhibition in the first patient who developed acute renal failure. The second patient with acute on chronic renal failure developed an intracerebral hemorrhage. Normal platelet aggregation was restored after acute hemodialysis. In a third patient with end-stage renal disease, platelet function returned to the normal range following hemodialysis. There is a prolonged time course to the restoration of normal platelet aggregation in patients with severe renal dysfunction who are treated with eptifibatide. Acute renal hemodialysis may reverse the inhibitory effect of eptifibatide on platelet aggregation in these patients. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:459 / 462
页数:4
相关论文
共 9 条
[1]   IMMEDIATE AND REVERSIBLE PLATELET INHIBITION AFTER INTRAVENOUS ADMINISTRATION OF A PEPTIDE GLYCOPROTEIN IIB/IIIA INHIBITOR DURING PERCUTANEOUS CORONARY INTERVENTION [J].
HARRINGTON, RA ;
KLEIMAN, NS ;
KOTTKEMARCHANT, K ;
LINCOFF, AM ;
TCHENG, JE ;
SIGMON, KN ;
JOSEPH, D ;
RIOS, G ;
TRAINOR, K ;
ROSE, D ;
GREENBERG, CS ;
KITT, MM ;
TOPOL, EJ ;
CALIFF, RM .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (17) :1222-1227
[2]  
Kereiakes DJ, 1996, J AM COLL CARDIOL, V27, P536
[3]   Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease [J].
Lincoff, AM ;
Califf, RM ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (05) :1103-1115
[4]   Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade [J].
Mascelli, MA ;
Lance, ET ;
Damaraju, L ;
Wagner, CL ;
Weisman, HF ;
Jordan, RE .
CIRCULATION, 1998, 97 (17) :1680-1688
[5]  
MERCK, 2000, AGGRASTAT PACKAGE IN
[6]   MK-383 (L-700,462), A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB/IIIA ANTAGONIST, IS ACTIVE IN MAN [J].
PEERLINCK, K ;
DELEPELEIRE, I ;
GOLDBERG, M ;
FARRELL, D ;
BARRETT, J ;
HAND, E ;
PANEBIANCO, D ;
DECKMYN, H ;
VERMYLEN, J ;
ARNOUT, J .
CIRCULATION, 1993, 88 (04) :1512-1517
[7]   Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina - A randomized multicenter trial [J].
Schulman, SP ;
GoldschmidtClermont, PJ ;
Topol, EJ ;
Califf, RM ;
Navetta, FI ;
Willerson, JT ;
Chandra, NC ;
Guerci, AD ;
Ferguson, JJ ;
Harrington, RA ;
Lincoff, AM ;
Yakubov, SJ ;
Bray, PF ;
Bahr, RD ;
Wolfe, CL ;
Yock, PG ;
Anderson, HV ;
Nygaard, TW ;
Mason, SJ ;
Effron, MB ;
Fatterpacker, A ;
Raskin, S ;
Smith, J ;
Brashears, L ;
Gottdiener, P ;
duMee, C ;
Kitt, MM ;
Gerstenblith, G .
CIRCULATION, 1996, 94 (09) :2083-2089
[8]   A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban [J].
Simon, DI ;
Liu, CB ;
Ganz, P ;
Kirshenbaum, JM ;
Piana, RN ;
Rogers, C ;
Selwyn, AP ;
Popma, JJ .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2001, 52 (04) :425-432
[9]   Rapid platelet-function assay - An automated and quantitative cartridge-based method [J].
Smith, JW ;
Steinhubl, SR ;
Lincoff, AM ;
Coleman, JC ;
Lee, TT ;
Hillman, RS ;
Coller, BS .
CIRCULATION, 1999, 99 (05) :620-625